An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of rivaroxaban (XARELTO®) initiated in secondary care for the prevention of atherothrombotic events in patients who have had acute coronary syndrome in England and Wales (ROSE ACS)

31/07/2015
23/04/2024
EU PAS number:
EUPAS9977
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

ACS SCEM Final_30_08_2017_version 7_Clean

English (846.95 KB - PDF) View document
Study results
Study results

17542_EU PAS Abstract_Redacted_V1.0_2019-11-21

English (296.37 KB - PDF) View document

DSRU SCEM ACS - Abstract Final Report

English (125.94 KB - PDF) View document
Study report
Study report

17542_Clinical Study Report_Redacted_V1.0_2019-11-21

English (8.37 MB - PDF) View document

DSRU EUPAS9977 - Summary Interim Report_3Feb2019

English (86.12 KB - PDF) View document
Other information
Study, other information

DSRU EUPAS9977 - Summary Interim Report_3Feb2019.pdf

English (86.12 KB - PDF) View document